Ophthalmic complications of targeted cancer therapy and recently recognized ophthalmic complications of traditional chemotherapy

Survey of Ophthalmology

Volumn 59, Issue 5, 2014, Pages 493-502

  Kheir, Wajiha J ^a,b   Sniegowski, Matthew C ^a   El Sawy, Tarek ^a,c   Li, Alexa ^a   Esmaeli, Bita ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^c STANFORD UNIVERSITY   (United States)

Author keywords

Cancer therapy; Ocular adverse effect; Targeted therapy

Indexed keywords

B RAF KINASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; CETUXIMAB; DABRAFENIB; DENILEUKIN DIFTITOX; DIURETIC AGENT; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; IMATINIB; IPILIMUMAB; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; PANITUMUMAB; PERIFOSINE; PIMASERTIB; RITUXIMAB; SORAFENIB; STEROID; TRAMETINIB; TRASTUZUMAB; VEMURAFENIB; ZOLEDRONIC ACID; ANTINEOPLASTIC AGENT;

ACNE; ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ARTHROPATHY; BLEPHARITIS; BLURRED VISION; BONE MARROW SUPPRESSION; BONE METASTASIS; BREAST CANCER; BRONCHOSPASM; CANCER CHEMOTHERAPY; CANILICULAR STENOSIS; CENTRAL SEROUS RETINOPATHY; CHEMOSIS; CHORIORETINOPATHY; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; COLITIS; COLON CANCER; COLORECTAL CANCER; CONJUNCTIVAL HEMORRHAGE; CONJUNCTIVITIS; CONJUNCTIVOCHALASIS; CORNEA DISEASE; CORNEA EROSION; CORNEA INJURY; CORNEA THINNING; CORNEAL THINNING; CUTANEOUS T CELL LYMPHOMA; DERMATITIS; DIABETIC NEUROGENIC ARTHROPATHY; DIARRHEA; DIPLOPIA; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG WITHDRAWAL; DRY EYE; ECTROPION; EDEMA; ENDOCRINE OPHTHALMOPATHY; EPIPHORA; EPISCLERITIS; EXOPHTHALMOS; EYE CANCER; EYE DISEASE; EYE INFLAMMATION; EYE TOXICITY; EYELID DISEASE; EYELID EDEMA; EYELID RASH; FATIGUE; FEVER; FLUID RETENTION; GASTROINTESTINAL STROMAL TUMOR; HEAD AND NECK CANCER; HEPATITIS; HUMAN; HYPEREMIA; HYPOPHYSITIS; IMMUNOPATHOLOGY; INFUSION RELATED REACTION; INTRAOCULAR METASTASIS; IRIDOCYCLITIS; ISCHEMIC OPTIC NEUROPATHY; KERATITIS; KIDNEY CARCINOMA; LACRIMAL DUCT OCCLUSION; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MERKEL CELL TUMOR; METASTATIC MELANOMA; MOLECULARLY TARGETED THERAPY; MULTICENTER STUDY (TOPIC); MULTIPLE MYELOMA; NAUSEA; NONHODGKIN LYMPHOMA; NONHUMAN; OPEN ANGLE GLAUCOMA; OPTIC NEURITIS; ORBIT EDEMA; ORBIT INFLAMMATION; OSTEOPOROSIS; OUTCOME ASSESSMENT; PAGET BONE DISEASE; PANCREAS CANCER; PAPILLEDEMA; PAPILLITIS; PERIORBITAL DERMATITIS; PERIORBITAL EDEMA; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PIGMENTARY RETINOPATHY; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PROGRESSIVE CORNEAL RING INFILTRATE; PROSTATE CANCER; PRURITUS; PUNCTATE KERATITIS; RASH; RETINA EDEMA; RETINA HEMORRHAGE; RETINA MACULA CYSTOID EDEMA; RETINA MACULA DEGENERATION; RETINA MACULA EDEMA; RETINA MACULA ISCHEMIA; RETINA MACULOPATHY; RETINA VEIN OCCLUSION; RETINOPATHY; REVIEW; RISK BENEFIT ANALYSIS; SCLERA DISEASE; SCLERAL EDEMA; SCLERITIS; SIDE EFFECT; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; STOMACH CANCER; THYROID CANCER; TREATMENT RESPONSE; TRICHIASIS; TRICHOMEGALY; ULCERATIVE KERATITIS; UVEITIS; VISUAL DISORDER; VISUAL IMPAIRMENT; WALDENSTROEM MACROGLOBULINEMIA; ADVERSE EFFECTS; CHEMICALLY INDUCED; NEOPLASMS;

ANTINEOPLASTIC AGENTS; EYE DISEASES; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS;

EID: 84905973007     PISSN: 00396257     EISSN: 18793304     Source Type: Journal    
DOI: 10.1016/j.survophthal.2014.02.004     Document Type: Review

References (111)

1. Akinleye A., Furqan M., Mukhi N., et al. MEK and the inhibitors: from bench to bedside. JHematol Oncol 2013, 6:27.
2. Anforth R., Fernandez-Peñas P., Long G. Cutaneous toxicities of RAF inhibitors. Lancet Oncol 2013, 14:e11-e18.
3. Arnault J.P., Wechsler J., Escudier B., et al. Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib. JClin Oncol 2009, 27:e59-e61.
4. Babu K.G., Attili V.S.S., Bapsy P.P., et al. Imatinib-induced optic neuritis in a patient with chronic myeloid leukemia. Int Ophthalmol 2007, 27:43-44.
5. Belum V.R., Fischer A., Choi J.N., et al. Dermatological adverse events from BRAF inhibitors: a growing problem. Curr Oncol Rep 2013, 15:249-259.
6. Bonner J.A., Harari P.M., Giralt J., et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. NEngl J Med 2006, 354:567-578.
7. Borkar D.S., Lacouture M.E., Basti S. Spectrum of ocular toxicities from epidermal growth factor receptor inhibitors and their intermediate-term follow-up: a five-year review. Support Care Cancer 2013, 21:1167-1174.
8. Borodic G., Hinkle D.M., Cia Y. Drug-induced Graves disease from CTLA-4 receptor suppression. Ophthal Plast Reconstr Surg 2011, 27:e87-e88.
9. Boussemart L., Routier E., Mateus C., et al. Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients. Ann Oncol 2013, 24:1691-1697.
10. Bouwhuis M.G., Ten Hagen T.L., Suciu S., et al. Autoimmunity and treatment outcome in melanoma. Curr Opin Oncol 2011, 23:170-176.
11. Burris H.A., Rugo H.S., Vukelja S.J., et al. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. JClin Oncol 2011, 29:398-405.
12. Burstein H.J., Manola J., Younger J., et al. Docetaxel administered on a weekly basis for metastatic breast cancer. JClin Oncol 2000, 18:1212-1219.
13. Bussone G., Kaswin G., de Menthon M., et al. Macular oedema following rituximab infusion in two patients with Wegener's granulomatosis. Clin Exp Rheumatol 2010, 28(1 Suppl 57):90-92.
14. Chu E.Y., Wanat K.A., Miller C.J., et al. Diverse cutaneous side effects associated with BRAF inhibitor therapy: a clinicopathologic study. JAm Acad Dermatol 2012, 67:1265-1272.
15. De Vita F., Giuliani F., Silvestris N., et al. Human epidermal growth factor receptor 2 (HER2) in gastric cancer: A new therapeutic target. Cancer Treat Rev 2010, 36(Suppl 3):S11-S15.
16. Demetri G.D., Mehren M., Blanke C.D., et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. NEngl J Med 2002, 347:472-480.
17. Di Giacomo A.M., Biagioli M., Maio M. The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications. Semin Oncol 2010, 37:499-507.
18. Dogan S.S., Esmaeli B. Ocular side effects associated with imatinib mesylate and perifosine for gastrointestinal stromal tumor. Hematol Oncol Clin North Am 2009, 23:109-114.
19. Esmaeli B., Ahmadi M.A., Rivera E., et al. Docetaxel secretion in tears: association with lacrimal drainage obstruction. Arch Ophthalmol 2002, 120:1180-1182.
20. Esmaeli B., Amin S., Valero V., et al. Prospective study of incidence and severity of epiphora and canalicular stenosis in patients with metastatic breast cancer receiving docetaxel. JClin Oncol 2006, 24:3619-3622.
21. Esmaeli B., Diba R., Ahmadi M.A., et al. Periorbital oedema and epiphora as ocular side effects of imatinib mesylate (Gleevec). Eye 2004, 18:760-762.
22. Esmaeli B., Golio D., Lubecki L., et al. Canalicular and nasolacrimal duct blockage: an ocular side effect associated with the antineoplastic drug S-1. Am J Ophthalmol 2005, 140:325-327.
23. Esmaeli B., Hidaji L., Adinin R.B., et al. Blockage of the lacrimal drainage apparatus as a side effect of docetaxel therapy. Cancer 2003, 98:504-507.
24. Esmaeli B., Hortobagyi G., Esteva F., et al. Canalicular stenosis secondary to weekly docetaxel: a potentially preventable side effect. Ann Oncol 2002, 13:218-221.
25. Esmaeli B., Prieto V.G., Butler C.E., et al. Severe periorbital edema secondary to STI571 (Gleevec). Cancer 2002, 95:881-887.
26. Esmaeli B. Docetaxel induced histologic changes in the lacrimal sac and the nasal mucosa. Ophthal Plast Reconstr Surg 2003, 19:305-308.
27. Esmaeli B. Management of excessive tearing as a side effect of docetaxel. Clin Breast Cancer 2005, 5:455-457.
28. Fabre-Guillevin E., Tchen N., Anibali-Charpiat M.F., et al. Taxane-induced glaucoma. Lancet 1999, 354:1181-1182.
29. Falchook G.S., Lewis K.D., Infante J.R., et al. Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol 2012, 13:782-789.
30. Falchook G.S., Long G.V., Kurzrock R., et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 2012, 379:1893-1901.
31. Flaherty K.T., Robert C., Hersey P., et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. NEngl J Med 2012, 367:107-114.
32. Foerster C.G., Cursiefen C., Kruse F.E. Persisting corneal erosion under cetuximab (Erbitux) treatment (epidermal growth factor receptor antibody). Cornea 2008, 27:612-614.
33. Fraunfelder F.T., Fraunfelder F.W. Trichomegaly and other external eye side effects associated with epidermal growth factor. Cutan Ocul Toxicol 2012, 31:195-197.
34. Fraunfelder F.W., Fraunfelder F.T. Bisphosphonates and ocular inflammation. NEngl J Med 2003, 348:1187-1188.
35. Fraunfelder F.W., Solomon J., Druker B.J., et al. Ocular side-effects associated with imatinib mesylate (Gleevec). JOcul Pharmacol Ther 2003, 19:371-375.
36. Garibaldi D.C., Adler R.A. Cicatricial ectropion associated with treatment of metastatic colorectal cancer with cetuximab. Ophthal Plast Reconstr Surg 2007, 23:62-63.
37. Guarneri V., Barbieri E., Dieci M.V., et al. Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer. Cancer Treat Rev 2010, 36(Suppl 3):S62-S66.
38. Haura E.B., Ricart A.D., Larson T.G., et al. Aphase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer. Clin Cancer Res 2010, 16:2450-2457.
39. Hemmati I., Wade J., Kelsall J. Risedronate-associated scleritis: a case report and review of the literature. Clin Rheumatol 2012, 31:1403-1405.
40. Ho W.L., Wong H., Yau T. The ophthalmological complications of targeted agents in cancer therapy: what do we need to know as ophthalmologists?. Acta Ophthalmol 2013, 91:604-609.
41. Hong D.S., Reddy S.B., Prieto V.G., et al. Multiple squamous cell carcinomas of the skin after therapy with sorafenib combined with tipifarnib. Arch Dermatol 2008, 144:779-782.
42. Huang W., Yang A.H., Matsumoto D., et al. PD0325901, a mitogen-activated protein kinase kinase inhibitor, produces ocular toxicity in a rabbit animal model of retinal vein occlusion. JOcul Pharmacol Ther 2009, 25:519-530.
43. Infante J.R., Fecher L.A., Falchook G.S., et al. Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. Lancet Oncol 2012, 13:773-781.
44. Infante J.R., Papadopoulos K.P., Bendell J.C., et al. Aphase 1b study of trametinib, an oral mitogen-activated protein kinase kinase (MEK) inhibitor, in combination with gemcitabine in advanced solid tumours. Eur J Cancer 2013, 49:2077-2085.
45. Johnson K.S., Levin F., Chu D.S. Persistent corneal epithelial defect associated with erlotinib treatment. Cornea 2009, 28:706-707.
46. Kaur H., Uy C., Kelly J., et al. Orbital inflammatory disease in a patient treated with zoledronate. Endocr Pract 2011, 17:e101-e103.
47. Keenan J.D., Fram N.R., McLeod S.D., et al. Perifosine-related rapidly progressive corneal ring infiltrate. Cornea 2010, 29:583-585.
48. Kim N., Park C., Park D.J., et al. Lacrimal drainage obstruction in gastric cancer patients receiving S-1 chemotherapy. Ann Oncol 2012, 23:2065-2071.
49. Kusumi E., Arakawa A., Kami M., et al. Visual disturbance due to retinal edema as a complication of imatinib [letter]. Leukemia 2004, 18:1138-1139.
50. Kwon S., Lee D., Kim Y. Optic disc edema as a possible complication of imatinib mesylate (Gleevec). Jpn J Ophthalmol 2008, 52:331-333.
51. Lacouture M.E., O'Reilly K., Rosen N., et al. Induction of cutaneous squamous cell carcinomas by RAF inhibitors: cause for concern?. JClin Oncol 2012, 30:329-330.
52. Larson J.S., Bergstrom L.K., Cameron J.D., et al. Severe periorbital edema secondary to imatinib mesylate for chronic myelogenous leukemia. Arch Ophthalmol 2007, 125:985-986.
53. Leyssens B., Wildiers H., Lobelle J.P., et al. Adouble-blind randomized phase II study on the efficacy of topical eye treatment in the prevention of docetaxel-induced dacryostenosis. Ann Oncol 2010, 21:419-423.
54. Long G.V., Trefzer U., Davies M.A., et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol 2012, 13:1087-1095.
55. LoRusso P.M., Krishnamurthi S.S., Rinehart J.J., et al. Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers. Clin Cancer Res 2010, 16:1924-1937.
56. Macarulla T., Tabernero J., Cervantes A., et al. Phase I/II study of FOLFIRI plus the MEK 1/2 inhibitor pimasertib (MSC1936369B) as second-line treatment for Kras mutated metastatic colorectal cancer. Ann Oncol 2012, 23(Suppl 4):iv19-iv30.
57. Maker A.V., Yang J.C., Sherry R.M., et al. Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma. JImmunother 2006, 29:455-463.
58. Maloney D.G., Grillo-Lopez A.J., White C.A., et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997, 90:2188-2195.
59. Masood I., Negi A., Dua H. Imatinib as a cause of cystoid macular edema following uneventful phacoemulsification surgery. JCataract Refract Surg 2005, 31:2427-2428.
60. McClelland C.M., Harocopos G.J., Custer P.L. Periorbital edema secondary to imatinib mesylate. Clin Ophthalmol 2010, 4:427-431.
61. Methvin A.B., Gausas R.E. Newly recognized ocular side effects of erlotinib. Ophthal Plast Reconstr Surg 2007, 23:63-65.
62. Moore M.J., Goldstein D., Hamm J., et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. JClin Oncol 2007, 25:1960-1966.
63. Morris L.G., Höchster H.S., DeLacure M.D. Eyelash trichomegaly secondary to panitumumab therapy. Curr Oncol 2011, 18:145-146.
64. Murillas R., Larcher F., Conti C.J., et al. Expression of a dominant negative mutant of epidermal growth factor receptor in the epidermis of transgenic mice elicits striking alterations in hair follicle development and skin structure. EMBO J 1995, 14:5216-5223.
65. Musolino A., Ciccolallo L., Panebianco M., et al. Multifactorial central nervous system recurrence susceptibility in patients with HER2-positive breast cancer: epidemiological and clinical data from a population-based cancer registry study. Cancer 2011, 117:1837-1846.
66. Nakamura Y., Sotozono C., Kinoshita S. The epidermal growth factor receptor (EGFR): role in corneal wound healing and homeostasis. Exp Eye Res 2001, 72:511-517.
67. Ng J. Orbital and periorbital side effects of chemotherapy. Ophthalmic Oncology 2010, 327-337. Springer-Verlag, Berlin. B. Esmaeli (Ed.).
68. Olsen E., Duvic M., Frankel A., et al. Pivotal phase III trial oftwo dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. JClin Oncol 2001, 19:376-388.
69. Oribe N., Tanimoto T.E., Shimoda K., et al. Edema of the eyelids and sclera after rituximab infusion for orbital MALT lymphoma. Haematologica 2004, 89(6 Suppl):EIM14.
70. Park M., Liu G.T., Piltz-Seymour J., et al. Vision loss following denileukin diftitox treatment: a case report of possible posterior ischemic optic neuropathy. Leuk Lymphoma 2007, 48:808-811.
71. Pascual J.C., Bañuls J., Belinchon I., et al. Trichomegaly following treatment with gefitinib (ZD1839). Br J Dermatol 2004, 151:1111-1112.
72. Patel D.V., Horne A., House M., et al. The incidence of acute anterior uveitis after intravenous zoledronate. Ophthalmology 2013, 120:773-776.
73. Pazianas M., Clark E.M., Eiken P.A., et al. Inflammatory eye reactions in patients treated with bisphosphonates and other osteoporosis medications: cohort analysis using a national prescription database. JBone Miner Res 2013, 28:455-463.
74. Pérez-Fidalgo J.A., Vila Arteaga J., Chirivella González I., et al. Breast cancer metastases in the iris: does treatment modifies natural history of the illness?. An Med Interna 2008, 25:178-180.
75. Phillips P.M., Newman S.A. Orbital inflammatory disease after intravenous infusion of zoledronate for treatment of metastatic renal cell carcinoma. Arch Ophthalmol 2008, 126:137-139.
76. Pietras K., Ostman A., Sjoquiest M., et al. Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res 2001, 61:2929-2934.
77. Procianoy F., Procianoy E. Orbital inflammatory disease secondary to a single-dose administration of zoledronic acid for treatment of postmenopausal osteoporosis. Osteoporos Int 2010, 21:1057-1058.
78. Radaelli F., Vener C., Ripamonti F., et al. Conjunctival hemorrhagic events associated with imatinib mesylate. Int J Hematol 2007, 86:390-393.
79. Ravnan M.C., Matalka M.S. Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma. Clin Ther 2012, 34:1474-1486.
80. Reid I.R., Gamble G.D., Mesenbrink P., et al. Characterization of and risk factors for the acute-phase response after zoledronic acid. JClin Endocrinol Metab 2010, 95:4380-4387.
81. Renouf D.J., Velazquez-Martin J.P., Simpson R., et al. Ocular toxicity of targeted therapies. JClin Oncol 2012, 30:3277-3286.
82. Robert C., Arnault J.P., Mateus C. RAF inhibition and induction of cutaneous squamous cell carcinoma. Curr Opin Oncol 2011, 23:177-182.
83. Robinson M.R., Chan C.C., Yang J.C., et al. Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: a new cause of uveitis. JImmunother 2004, 27:478-479.
84. Rodt S.A., Ahlen K., Berg A., et al. Anovel physiological function for platelet-derived growth factor BB in rat dermis. JPhysiol 1996, 495:193-200.
85. Roth D., Akbari S., Rothstein A. Macular ischemia associated with imatinib mesylate therapy for chronic myeloid leukemia. Retin Cases Brief Rep 2009, 3:161-164.
86. Ruddle J.B., Harper C.A., Hönemann D., et al. Adenileukin diftitox (Ontak) associated retinopathy?. Br J Ophthalmol 2006, 90:1070-1071.
87. Ruddle J.B., Prince H.M. Denileukin diftitox and vision loss. Leuk Lymphoma 2007, 48:655-656.
88. Saleh M., Bourcier T., Noel G., et al. Bilateral macular ischemia and severe visual loss following trastuzumab therapy. Acta Oncol 2011, 50:477-478.
89. Sasaki T., Miyashita H., Miyanaga T., et al. Dacryoendoscopic observation and incidence of canalicular obstruction/stenosis associated with S-1, an oral anticancer drug. Jpn J Ophthalmol 2012, 56:214-218.
90. Sharma N.S., Ooi J.L., Masselos K., et al. Zoledronic acid infusion and orbital inflammatory disease. NEngl J Med 2008, 359:1410-1411.
91. Savar A., Esmaeli B. Eyelid malposition: unique scenarios in cancer patients. Ophthalmic Oncology 2010, 251-258. Springer-Verlag, Berlin. B. Esmaeli (Ed.).
92. Shepherd F.A., Rodrigues J., Ciuleanu T., et al. Erlotinib in previously treated non-small cell lung cancer. NEngl J Med 2005, 353:123-132.
93. Shome D., Trent J., Espandar L., et al. Ulcerative keratitis in gastrointestinal stromal tumor patients treated with perifosine. Ophthalmology 2008, 115:483-487.
94. Skolnick C.A., Doughman D.J. Erosive conjunctivitis and punctal stenosis secondary to docetaxel (Taxotere). Eye Contact Lens 2003, 29:134-135.
95. Smith K.J., Haley H., Hamza S., et al. Eruptive keratoacanthoma-type squamous cell carcinomas in patients taking sorafenib for the treatment of solid tumors. Dermatol Surg 2009, 35:1766-1770.
96. Specenier P., Koppen C., Vermorken J.B. Diffuse punctate keratitis in a patient treated with cetuximab as monotherapy. Ann Oncol 2007, 18:961-962.
97. Stahl J.L., Cook E.B., Graziano F.M., et al. Human conjunctival mast cells: expression of Fc epsilonRI, c-kit, ICAM-1, and IgE. Arch Ophthalmol 1999, 117:493-497.
98. Subramanian P.S., Kerrison J.B., Calvert P.C., et al. Orbital inflammatory disease after pamidronate treatment for metastatic prostate cancer. Arch Ophthalmol 2003, 121:1335-1336.
99. Teitelbaum B.A., Tresley D.J. Cystic maculopathy with normal capillary permeability secondary to docetaxel. Optom Vis Sci 2003, 80:277-279.
100. Telander D.G., Sarraf D. Cystoid macular edema with docetaxel chemotherapy and the fluid retention syndrome. Semin Ophthalmol 2007, 22:151-153.
101. Tobinai K., Kobayashi Y., Narabayashi M., et al. Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma. The IDEC-C2B8 Study Group. Ann Oncol 1998, 9:527-534.
102. Tsalic M., Gilboa M., Visel B., et al. Epiphora (excessive tearing) and other ocular manifestations related to weekly docetaxel: underestimated dose-limiting toxicity. Med Oncol 2006, 23:57-61.
103. Tsoucalas G.I., Tzovaras A.A., Ntokou A.P., et al. Dacryoscintigraphy for the detection of ocular drainage system stenosis induced by docetaxel and fluorouracil. Hell J Nucl Med 2012, 15:159-161.
104. Tullo A.B., Esmaeli B., Murray Pl, et al. Ocular findings in patients with solid tumours treated with the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD 1839) in phase I and II clinical trials. Eye (Lond) 2005, 19:729-738.
105. Vaccaro M., Pollicino A., Barbuzza O., et al. Trichomegaly of the eyelashes following treatment with cetuximab. Clin Exp Dermatol 2009, 34:402-403.
106. Van Cutsem E., Peeters M., Siena S., et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. JClin Oncol 2007, 25:1658-1664.
107. Vano-Galvan S., Rios-Buceta L., Ma D.L., et al. Cetuximab-induced hypertrichosis of the scalp and eyelashes. JAm Acad Dermatol 2010, 62:531-533.
108. Voskens C.J., Goldinger S.M., Loquai C., et al. The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. PLoS One 2013, 8:e53745.
109. Weber J. Ipilimumab: controversies in its development, utility and autoimmune adverse events. Cancer Immunol Immunother 2009, 58:823-830.
110. Yeo J., Jafer A.K. Zolendronate associated inflammatory orbital disease. NZ Med J 2010, 123:50-52.
111. Zhang G., Basti S., Jampol L.M. Acquired trichomegaly and symptomatic external ocular changes in patients receiving epidermal growth factor receptor inhibitors: case reports and a review of literature. Cornea 2007, 26:858-860.